These results indicated that the increase in TIGIT on PB NK cells together with the increase in CD57 on BM NK cells may explain the subdued NK cell antileukemia capacity and proliferation ability in DN-CML patients. Here, B3GAT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.